石遠(yuǎn)凱，1960年生，籍貫遼寧營(yíng)口，腫瘤內(nèi)科學(xué)家，中國(guó)醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院醫(yī)生，博士生導(dǎo)師。1978年考入中國(guó)醫(yī)科大學(xué)日文醫(yī)學(xué)專業(yè)，1984年獲得學(xué)士學(xué)位。1985年在中國(guó)醫(yī)科大學(xué)腫瘤學(xué)專業(yè)攻讀碩士學(xué)位，從事臨床腫瘤學(xué)研究。1988年在中國(guó)協(xié)和醫(yī)科大學(xué)腫瘤學(xué)專業(yè)攻讀博士學(xué)位，從事腫瘤內(nèi)科研究。1989年進(jìn)入日本大阪大學(xué)攻讀聯(lián)合培養(yǎng)博士研究生。1992年就職于中國(guó)醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院，聘主治醫(yī)師。1994年升為副主任醫(yī)師。1998年升為主任醫(yī)師。

淋巴瘤、肺癌、頭頸部癌等實(shí)體腫瘤靶向治療、免疫治療等內(nèi)科治療新療法和新方案，抗腫瘤新藥臨床試驗(yàn)及療效相關(guān)分子標(biāo)志物，基于臨床和分子遺傳學(xué)特征的患者療效及預(yù)后評(píng)價(jià)體系和個(gè)體化精準(zhǔn)治療。

午夜92福利1000,午夜92福利1000,久久国产亚洲高清观看5388,美女不拍网站免费观看,欧美***天天久久综合精品,中文字幕日韩系列中文字幕,综合久久国产九一剧情麻豆,丰满人妻在线免费视频,奶子大逼又嫩操起来真爽

1. Shi Y#*, Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, Zhu S, Zhang X, Li Y, Liu J, Cao L, Cheng Y, Zhao H, Zhang S, Zang A, Cui J, Feng J, Yang N, Liu F, Jiang Y, Gu C. Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR mutated non-small cell lung cancer: results from the FURLONG study. J Thorac Oncol. 2022, S1556-0864(22)01496-4. (IF=20.121)

2. Shi Y#*, Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, Zhu S, Zhang X, Li Y, Liu J, Cao L, Cheng Y, Zhao H, Zhang S, Zang A, Cui J, Feng J, Yang N, Liu F, Jiang Y, Gu C. FURLONG investigators. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir Med. 2022, S2213-2600(22)00168-0. (IF=102.642,PIII)

3. Shi Y#*, Li B, Wu L, Pan Y, Pan Z, Liu Y, Fan Y, Ji Y, Fang J, Shi Q, Shi J, Gao H, Hu Y, Wang X, He Z, Ma R, Zhang Y, Jiang D, Bai Y, Zhang Y, Huang L, Zhou T, Liu H, Wang D, Wen Q, Chen G, Zang A, Wang X, Zhang X, Hu J, Yang R, Zhang G, Gu K, Wang L, Wang Q, Wei Z, Li Z, Lu H, Zhang H, Chen H, Song T. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study. J Thorac Oncol. 2022, S1556-0864(22)00267-2. (IF=20.121)

4. Shi Y#*, Zhao Y, Yang S, Zhou J, Zhang L, Chen G, Fang J, Zhu B, Li X, Shu Y, Shi J, Zheng R, Wang D, Yu H, Huang J, Zhuang Z, Wu G, Zhang L, Guo Z, Greco M, Li X, Zhang Y. Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study. J Thorac Oncol. 2022, 17(5):708-717. (IF=20.121)

5. Shi Y#*, Fang J, Hao X, Zhang S, Liu Y, Wang L, Chen J, Hu Y, Hang X, Li J, Liu C, Zhang Y, Wang Z, Hu Y, Gu K, Huang J, Zhang L, Shan J, Ouyang W, Zhao Y, Zhuang W, Yu Y, Zhao J, Zhang H, Lu P, Li W, Si M, Ge M, Geng H. Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. Signal Transduct Target Ther. 2022, 7(1):25. (IF=38.104)

6. Shi Y#*, Lei K, Jia Y, Ni B, He Z, Bi M, Wang X, Shi J, Zhou M, Sun Q, Wang G, Chen D, Shu Y, Liu L, Guo Z, Liu Y, Yang J, Wang K, Xiao K, Wu L, Yi T, Sun D, Kang M, Ma T, Mao Y, Shi J, Tang T, Wang Y, Xing P, Lv D, Liao W, Luo Z, Wang B, Wu X, Zhu X, Han S, Guo Q, Liu R, Lu Z, Zhang J, Fang J, Hu C, Ji Y, Liu G, Lu H, Wu D, Zhang J, Zhu S, Liu Z, Qiu W, Ye F, Yu Y, Zhao Y, Zheng Q, Chen J, Pan Z, Zhang Y, Lian W, Jiang B, Qiu B, Zhang G, Zhang H, Chen Y, Chen Y, Duan H, Li M, Liu S, Ma L, Pan H, Yuan X, Yuan X, Zheng Y, Gao E, Zhao L, Wang S, Wu C. Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial. Cancer Commun (Lond). 2021, 41(9):889-903. (IF=15.283)

7. Shi Y#*, Hu X, Zhang S, Lv D, Wu L, Yu Q, Zhang Y, Liu L, Wang X, Cheng Y, Ma Z, Niu H, Wang D, Feng J, Huang C, Liu C, Zhao H, Li J, Zhang X, Jiang Y, Gu C. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respir Med. 2021, 9(8):829-839. (IF=102.642)

8. Shi Y#*, Wu J, Wang Z, Zhang L, Wang Z, Zhang M, Cen H, Peng Z, Li Y, Fan L, Guo Y, Ma L, Cui J, Gao Y, Yang H, Zhang H, Wang L, Zhang W, Zhang H, Xie L, Jiang M, Zhou H, Shuang Y, Su H, Ke X, Jin C, Du X, Du X, Liu L, Xi Y, Ge Z, Feng R, Zhang Y, Zhou S, Xie F, Wang Q. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). J Hematol Oncol. 2021, 14(1):12. (IF=17.388)

9. Shi Y#*, Zhang S, Hu X, Feng J, Ma Z, Zhou J, Yang N, Wu L, Liao W, Zhong D, Han X, Wang Z, Zhang X, Qin S, Ying K, Feng J, Fang J, Liu L, Jiang Y. Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation. J Thorac Oncol. 2020, 15(6):1015-1026. (IF=13.357)

10.Shi Y#, Zhang L#, Liu X, Zhou C, Zhang L, Zhang S, Wang D, Li Q, Qin S, Hu C, Zhang Y, Chen J, Cheng Y, Feng J, Zhang H, Song Y, Wu YL, Xu N, Zhou J, Luo R, Bai C, Jin Y, Liu W, Wei Z, Tan F, Wang Y, Ding L, Dai H, Jiao S, Wang J, Liang L, Zhang W, Sun Y*. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013, 14(10):953-61. (IF=24.725,PIII)